Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

Heart failure, a leading cause of death in the US, can be triggered by cardiac amyloidosis, a condition often misdiagnosed as ...

A cardiologist spotlights cardiac amyloidosis, a protein disease often mistaken for hypertension. Learn the signs and how to get screened.

Heart failure, a condition where the heart doesn't pump blood efficiently, manifests through symptoms like shortness of ...

After combining three health behaviors and four health factors into a single cardiovascular health score, the AHA has ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

Discover how MemorialCare's Women's Heart Center at Long Beach is tackling the leading killer of women, heart disease, ...

The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure (HF). Now, another drug class has ...

Scientists have discovered that four health habits — which include sleep quality and nicotine use — were the most important ...